Macrophages exposed to hypoxia secrete proteoglycans for which LDL has higher affinity

Atherosclerosis

Volumn 215, Issue 1, 2011, Pages 77-81

  Asplund, Annika ^a   Fridén, Vincent ^a   Stillemark Billton, Pia ^a   Camejo, Germán ^a,b   Bondjers, Göran ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Hypoxia; LDL glycosaminoglycans interactions; Macrophages

Indexed keywords

GLYCOSAMINOGLYCAN; LOW DENSITY LIPOPROTEIN; OXYGEN; PROTEOGLYCAN;

ARTICLE; BINDING AFFINITY; BIOSYNTHESIS; CELL HYPOXIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; MACROPHAGE; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; SULFATION;

ANOXIA; ATHEROSCLEROSIS; CHONDROITIN SULFATES; CHROMATOGRAPHY, GEL; GLYCOSAMINOGLYCANS; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; PROTEOGLYCANS; SULFOTRANSFERASES;

EID: 79952104239     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.12.017     Document Type: Article

References (43)

1. Camejo G., Hurt-Camejo E., Wiklund O., Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998, 139:205-222.
2. Gustafsson M., Flood C., Jirholt P., Boren J. Retention of atherogenic lipoproteins in atherogenesis. Cell Mol Life Sci 2004, 61:4-9.
3. Oorni K., Kovanen P.T. Enhanced extracellular lipid accumulation in acidic environments. Curr Opin Lipidol 2006, 17:534-540.
4. Tabas I., Williams K.J., Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007, 116:1832-1844.
5. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002, 8:1211-1217.
6. Chang M.Y., Olin K.L., Tsoi C., Wight T.N., Chait A. Human monocyte-derived macrophages secrete two forms of proteoglycan-macrophage colony-stimulating factor that differ in their ability to bind low density lipoproteins. J Biol Chem 1998, 273:15985-15992.
7. Makatsori E., Lamari F.N., Theocharis A.D., et al. Large matrix proteoglycans, versican and perlecan, are expressed and secreted by human leukemic monocytes. Anticancer Res 2003, 23:3303-3309.
8. Uhlin-Hansen L, Wik T., Kjellen L., et al. Proteoglycan metabolism in normal and inflammatory human macrophages. Blood 1993, 82:2880-2889.
9. Hurt-Camejo E., Camejo G., Rosengren B., et al. Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells. Arterioscler Thromb 1992, 12:569-583.
10. Hurt-Camejo E., Camejo G., Rosengren B., et al. Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J Lipid Res 1990, 31:1387-1398.
11. Owens R.T., Wagner W.D. Proteoglycans produced by cholesterol-enriched macrophages bind plasma low density lipoprotein. Atherosclerosis 1991, 91:229-240.
12. Hulten L.M., Levin M. The role of hypoxia in atherosclerosis. Curr Opin Lipidol 2009.
13. Sluimer J.C., Gasc J.M., van Wanroij J.L., et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol 2008, 51:1258-1265.
14. Leppanen O, Bjornheden T., Evaldsson M., et al. ATP depletion in macrophages in the core of advanced rabbit atherosclerotic plaques in vivo. Atherosclerosis 2006, 188:323-330.
15. Bjornheden T., Bondjers G. Oxygen consumption in aortic tissue from rabbits with diet-induced atherosclerosis. Arteriosclerosis 1987, 7:238-247.
16. Lewis J.S., Lee J.A., Underwood J.C., Harris A.L., Lewis C.E. Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol 1999, 66:889-900.
17. Asplund A., Stillemark-Billton P., Larsson E., et al. Hypoxic regulation of secreted proteoglycans in macrophages. Glycobiology 2010, 20:33-40.
18. Asplund A., Ostergren-Lunden G., Camejo G., Stillemark-Billton P., Bondjers G. Hypoxia increases macrophage motility, possibly by decreasing the heparan sulfate proteoglycan biosynthesis. J Leukoc Biol 2009, 86:381-388.
19. Turnbull J.E., Lyon M., Gallagher J.T. Structural analysis of glycosaminoglycans. Extracellular Matrix: A Practical Approach 1995, Oxford, IRL Press, p. 199-219.
20. Olofsson S.O., Bostrom K., Svanberg U., Bondjers G. Isolation and partial characterization of a polypeptide belonging to apolipoprotein B from low-density lipoproteins of human plasma. Biochemistry 1980, 19:1059-1064.
21. Hurt-Camejo E., Camejo G., Sartipy P. Measurements of proteoglycan-lipoprotein interaction by gel mobility shift assay. Methods Mol Biol 1998, 110:267-279.
22. Sartipy P., Johansen B., Camejo G., et al. Binding of human phospholipase A2 type II to proteoglycans. Differential effect of glycosaminoglycans on enzyme activity. J Biol Chem 1996, 271:26307-26314.
23. Pentikainen M.O., Oorni K., Lassila R., Kovanen P.T. The proteoglycan decorin links low density lipoproteins with collagen type I. J Biol Chem 1997, 272:7633-7638.
24. Kaji T., Sakurai S., Yamamoto C., et al. Characterization of chondroitin/dermatan sulfate proteoglycans synthesized by bovine retinal pericytes in culture. Biol Pharm Bull 2004, 27:1763-1768.
25. Hjerpe A., Antonopoulos C.A., Engfeldt B. Determination of sulphated disaccharides from chondroitin sulphates by high-performance liquid chromatography. J Chromatogr 1979, 171:339-344.
26. Wight T.N., Merrilees M.J. Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res 2004, 94:1158-1167.
27. Khalil M.F., Wagner W.D., Goldberg I.J. Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24:2211-2218.
28. Christner J.E. Biosynthesis of chondroitin sulfate proteoglycan by P388D1 macrophage-like cell line. Arteriosclerosis 1988, 8:535-543.
29. Maor I., Aviram M. Macrophage released proteoglycans are involved in cell-mediated aggregation of LDL. Atherosclerosis 1999, 142:57-66.
30. Maor I., Hayek T., Hirsh M., Iancu T.C., Aviram M. Macrophage-released proteoglycans enhance LDL aggregation: studies in aorta from apolipoprotein E-deficient mice. Atherosclerosis 2000, 150:91-101.
31. Figueroa J.E., Tao Z., Sarphie T.G., et al. Effect of hypoxia and hypoxia/reoxygenation on proteoglycan metabolism by vascular smooth muscle cells. Atherosclerosis 1999, 143:135-144.
32. Radhakrishnamurthy B., Srinivasan S.R., Vijayagopal P., Berenson G.S. Arterial wall proteoglycans-biological properties related to pathogenesis of atherosclerosis. Eur Heart J 1990, 11(Suppl. E):148-157.
33. Rodriguez-Lee M., Ostergren-Lunden G., Wallin B., et al. Fatty acids cause alterations of human arterial smooth muscle cell proteoglycans that increase the affinity for low-density lipoprotein. Arterioscler Thromb Vasc Biol 2005.
34. Srinivasan S.R., Xu J.H., Vijayagopal P., Radhakrishnamurthy B., Berenson G.S. Low-density lipoprotein binding affinity of arterial chondroitin sulfate proteoglycan variants modulates cholesteryl ester accumulation in macrophages. Biochim Biophys Acta 1995, 1272:61-67.
35. Stevens R.L., Razin E., Austen K.F., et al. Synthesis of chondroitin sulfate E glycosaminoglycan onto p-nitrophenyl-beta-d-xyloside and its localization to the secretory granules of rat serosal mast cells and mouse bone marrow-derived mast cells. J Biol Chem 1983, 258:5977-5984.
36. Halvorsen B., Aas U.K., Kulseth M.A., et al. Proteoglycans in macrophages: characterization and possible role in the cellular uptake of lipoproteins. Biochem J 1998, 331(Pt 3):743-752.
37. Jackson R.L., Busch S.J., Cardin A.D. Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev 1991, 71:481-539.
38. Tannock L.R., King V.L. Proteoglycan mediated lipoprotein retention: a mechanism of diabetic atherosclerosis. Rev Endocr Metab Disord 2008, 9:289-300.
39. Camejo G., Fager G., Rosengren B., Hurt-Camejo E., Bondjers G. Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J Biol Chem 1993, 268:14131-14137.
40. Kolset S.O., Ivhed I., Overvatn A., Nilsson K. Differentiation-associated changes in the expression of chondroitin sulfate proteoglycan in induced U-937 cells. Cancer Res 1988, 48:6103-6108.
41. Alves C.S., Mourao P.A. Interaction of high molecular weight chondroitin sulfate from human aorta with plasma low density lipoproteins. Atherosclerosis 1988, 73:113-124.
42. Fager G., Camejo G., Olsson U., et al. Binding of platelet-derived growth factor and low density lipoproteins to glycosaminoglycan species produced by human arterial smooth muscle cells. J Cell Physiol 1995, 163:380-392.
43. Iozzo R.V. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998, 67:609-652.